Canada markets open in 3 hours 38 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
966.30+2.75 (+0.29%)
At close: 04:00PM EDT
966.88 +0.58 (+0.06%)
After hours: 06:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close963.55
Open971.04
Bid966.08 x 100
Ask966.99 x 100
Day's Range962.41 - 976.75
52 Week Range684.81 - 998.33
Volume309,697
Avg. Volume503,318
Market Cap106.063B
Beta (5Y Monthly)0.11
PE Ratio (TTM)27.76
EPS (TTM)34.81
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,041.59
  • Zacks

    Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

    Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.

  • Simply Wall St.

    Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Reuters

    UPDATE 3-Regeneron's blood cancer therapy faces setback as FDA raises trial concerns

    Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing confirmatory trials. The FDA said in its response letter that it needs more data from enrollments in dose-finding and confirmatory portions of trials, delaying its decision on the drug, while confirming no issues with clinical efficacy or safety, trial design, labeling or manufacturing. The company was testing its experimental drug, odronextamab, in multiple late-stage trials in patients with follicular lymphoma and diffuse large B-cell lymphoma, the two most common subtypes of non-Hodgkin lymphoma.